Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

B.J. Monk, M.P. Barretina-Ginesta, B. Pothuri, I. Vergote, W. Graybill, M.R. Mirza, C.C. McCormick, D. Lorusso, R.G. Moore, G. Freyer, R.E. O’Cearbhaill, F. Heitz, D.M. O’Malley, A. Redondo, M.S. Shahin, C. Vulsteke, W.H. Bradley, C.A. Haslund, D.M. Chase, C. Pisano, L.L. Holman, M. J. Rubio Pérez, P. DiSilvestro, L. Gaba, T.J. Herzog, I. Bruchim, N. Compton, L. Shtessel, I.A. Malinowska, A. González-Martín

Open source

DOI: 10.1016/j.annonc.2024.08.2241
Published: 2024-11
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2024.08.2241,
  title = {Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial},
  author = {B.J. Monk and M.P. Barretina-Ginesta and B. Pothuri and I. Vergote and W. Graybill and M.R. Mirza and C.C. McCormick and D. Lorusso and R.G. Moore and G. Freyer and R.E. O’Cearbhaill and F. Heitz and D.M. O’Malley and A. Redondo and M.S. Shahin and C. Vulsteke and W.H. Bradley and C.A. Haslund and D.M. Chase and C. Pisano and L.L. Holman and M. J. Rubio Pérez and P. DiSilvestro and L. Gaba and T.J. Herzog and I. Bruchim and N. Compton and L. Shtessel and I.A. Malinowska and A. González-Martín},
  year = {2024},
  journal = {Annals of Oncology},
  doi = {10.1016/j.annonc.2024.08.2241},
  url = {https://doi.org/10.1016/j.annonc.2024.08.2241}
}

RIS

TY  - JOUR
TI  - Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
AU  - B.J. Monk
AU  - M.P. Barretina-Ginesta
AU  - B. Pothuri
AU  - I. Vergote
AU  - W. Graybill
AU  - M.R. Mirza
AU  - C.C. McCormick
AU  - D. Lorusso
AU  - R.G. Moore
AU  - G. Freyer
AU  - R.E. O’Cearbhaill
AU  - F. Heitz
AU  - D.M. O’Malley
AU  - A. Redondo
AU  - M.S. Shahin
AU  - C. Vulsteke
AU  - W.H. Bradley
AU  - C.A. Haslund
AU  - D.M. Chase
AU  - C. Pisano
AU  - L.L. Holman
AU  - M. J. Rubio Pérez
AU  - P. DiSilvestro
AU  - L. Gaba
AU  - T.J. Herzog
AU  - I. Bruchim
AU  - N. Compton
AU  - L. Shtessel
AU  - I.A. Malinowska
AU  - A. González-Martín
PY  - 2024
JO  - Annals of Oncology
DO  - 10.1016/j.annonc.2024.08.2241
UR  - https://doi.org/10.1016/j.annonc.2024.08.2241
ER  -

APA

Monk, B., Barretina-Ginesta, M., Pothuri, B., Vergote, I., Graybill, W., Mirza, M., McCormick, C., Lorusso, D., Moore, R., Freyer, G., O’Cearbhaill, R., Heitz, F., O’Malley, D., Redondo, A., Shahin, M., Vulsteke, C., Bradley, W., Haslund, C., Chase, D., Pisano, C., Holman, L., Pérez, M. J. R., DiSilvestro, P., Gaba, L., Herzog, T., Bruchim, I., Compton, N., Shtessel, L., Malinowska, I., & González-Martín, A. (2024). Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.08.2241

Source records

crossref · retrieved 2026-09-27T00:38:00.285Z